Clinical Trial Update: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sotatercept for anemia in patients with low- or intermediate-1 risk myelodysplastic syndromes and non-proliferative chronic myelomonocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2019-06-13